Research & Innovation - Participant Portal



Topic identifier: IMI2-2015-07-02
Publication date: 18 December 2015

Types of action: IMI2-RIA Research and Innovation action
Opening date:
18 December 2015
2nd stage Deadline:
17 March 2016 17:00:00
06 September 2016 17:00:00

Time Zone : (Brussels time)
  Horizon 2020 H2020 website
Pillar: Societal Challenges
Work Programme Year: H2020-JTI-IMI-2016
Work Programme Part: IMI2 Work Plan 2016
Topic Description
Specific Challenge:

In Alzheimer’s Disease (AD) extracellular depositions of amyloid beta peptides (plaques) and intracellular filamentous inclusions of tau (tangles) constitutes a hallmark of the disease. In Parkinson’s Disease (PD) the neuropathology is defined by intracellular inclusions of alpha-synuclein (Lewy bodies and Lewy neurites). Recently, new scientific opportunities to identify druggable targets have arisen based on the spreading and seeding hypothesis of tau and alpha-synuclein protein as prion-like proteins. This hypothesis allows setup of in vitro and in vivo models based on tau or alpha-synuclein pathological material isolated from patients, animal models or recombinant fibrils seeded into cells or animals and with a resulting defined mechanistic readout (spreading or seeding). Thus, it is envisioned that these models may be used in a screening setup to identify new targets and later validate their druggability. Advancing and focusing the research discoveries to identify drug targets related to Alzheimer’s and Parkinson’s disease requires multidisciplinary approaches including targets identification screens, tool compound development and validation in a wide range of experimental cell and animal disease models. The critical mass needed and availabilities of assay, models and reagents are only available through broad collaboration of public and private partners.


Our understanding of the molecular mechanisms involved in the spreading, uptake, seeding, aggregation, of tau and alpha-synuclein and their impact on cell homeostasis, release and toxicity is still very sparse, hence limiting effective intervention strategies. A key objective of the action will be to use the recent advances in setting up both in vitro and in vivo model systems for spreading and seeding processes. Genome-wide genetic screens and small molecule screens to identify targets and mechanism involved in these processes should be performed. Based on the key mechanisms identified in these screens, targets will be chosen for further validation of drugabbility and therapeutic potential in vitro and in vivo.

Expected Impact:

Several outputs from the project may contribute to the R&D process of developing new therapies against PD and AD. Establishing a common preclinical platform of assays based on the hypothesis of turnover / aggregation / spreading of misfolded pathological proteins is important to reach a consensus of how new treatment principles can best be evaluated and substantiated. Such a platform can form the basis for identification of new druggable targets which would open up for development of new innovative treatments against PD and AD.

Topic conditions and documents

Please read carefully all provisions below before the preparation of your application.

You can access the description of the different topics in the Call topics text.

The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section (page 78), as well as the following information : 

  1. List of countries and applicable rules for funding
  2. Eligibility and admissibility conditions
  3. Evaluation criteria and procedure, scoring and threshold : described in the IMI Manual for Submission, Evaluation and Grant award
  4. Indicative timetable for evaluation and grant agreement
  5. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

    IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):

    Summary of the most relevant provisions for participating in IMI2 actions
    Standard proposal template
    Standard evaluation form
    IMI2 Model Grant Agreement
    Template for Essential Clinical Trials Information

    MI2 Coordination and Support Action (IMI2-CSA):

    Summary of the most relevant provisions for participating in IMI2 actions
    Standard proposal template
    Standard evaluation form
    IMI2 Model Grant Agreement
    Template for Essential Clinical Trials Information


Submission Service

No submission system is open for this topic.

Get support

Contact the IMI Programme Office : E-mail: / Tel: +32 2 221 81 81

Contact IMI JU IT Helpdesk – for IMI2 topics contact the SOFIA IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

IMI States Representative Group (SRG) – contact you SRG member for assistance.

IMI Partner Search Tool
 helps you find a partner organisation for your proposal

National Contact Points (NCP) - 
contact your NCP for further assistance.

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding

Research Enquiry Service
– ask questions about. any aspect of European research in general and the EU Research Framework Programmes in particular.

– for compliance with ethical issues, check the information available on the Participant Portal , on the Science and Society Portal and in The European Charter for Researchers and the Code of Conduct for their recruitment

and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at